vimarsana.com
Home
Live Updates
Anbogen Secures 12.5 Million in Series A Funding, Advancing
Anbogen Secures 12.5 Million in Series A Funding, Advancing
Anbogen Secures 12.5 Million in Series A Funding, Advancing Precision Oncology Drug Development
TAIPEI, Jan. 31, 2024 /PRNewswire/ -- Anbogen Therapeutics, a clinical-stage biotechnology company specializing in groundbreaking cancer drug development,
Related Keywords
China ,
Taian ,
Shandong ,
Taipei ,
T Ai Pei ,
Taiwan ,
Thailand ,
Joe Shih ,
Angus Wu ,
Joe Hsueh ,
China Development Industrial Bank ,
Business Development ,
National Development Fund Business Angel Investment Program ,
National Research Program For Biopharmaceuticals ,
Anbogen Therapeutics ,
Taian Venture Capital ,
National Development Fund ,
Business Angel Investment Program ,
Implementation Project ,
Strengthening Investment ,
National Research Program ,
Tsu An Hsu ,
General Manager ,
Next Generation Sequencing ,
Media Inquiries ,
Please Contact ,
Thailand Business ,